An analysis of recent OCR enforcement actions and settlements identifies the common pitfalls labs should watch out for.
Subscribe today for access to
Articles and Reports
Kentucky $1.74 Million Settlement Illustrates the Danger of Billing Medicare for Nonmedical Urine Drug Tests
A recent False Claims Act settlement from Kentucky represents an unusual variation on a common theme.
In an analysis of enforcement actions from the end of 2022 to early spring 2023, cases involving urine drug testing were the most prevalent.
Recent OIG report suggests some labs might have gamed Medicare coverage rules in 2020 by billing for unusually high numbers of such tests.
In our latest roundup, schemes involving cancer genetic testing and kickbacks remain the most common, but there were some surprises.
Federal enforcement actions at the end of October and first two weeks of November featured some unusual characters.
Most of the recent settlements and enforcement actions involving labs related to medically unnecessary UDTs and genetic tests.
A recent $3.5 million settlement illustrates the kinds of pitfalls that can result in liability for hospital and freestanding sleep labs.
Recent case shows that fraud and kickback schemes involving CGx testing continue to be on the federal enforcement radar.
Most healthcare-related enforcement actions from July and August involved urine drug tests and genetic testing.
The OIG’s new Fraud Alert can help labs and other providers steer clear of potentially suspect arrangements with telemedicine companies.
The DOJ recently charged 21 defendants across the US for allegedly carrying out COVID-19 scams worth just under $150 million.